Y-111 (National Institutes of Health)

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameY-111 (National Institutes of Health)
Drug Alias NameY-111Y111Y 111
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of Health
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A